Leading the Way in Life Science Technologies

GEN Exclusives

More »

The Lists

More »
Sep 4, 2012

Top 20 Pharma-Friendly Congress Members

Who accepted the biggest pharmaceutical company contributions? Find out here.

Top 20 Pharma-Friendly Congress Members

These politicians accepted the most pharma dollars toward their campaigns. [© Ljupco Smokovski - Fotolia.com]

  • Below is a list of the 20 members of Congress (both Senate and House of Representatives) that have received the most in campaign contributions from pharmaceutical companies during the 2011–2012 election cycle, as recorded by OpenSecrets.org based on data from the Federal Election Commission available as of Aug. 6. Figures reflect contributions from both political action committees (PACs) and individuals giving $200 or more.

  • #20. Rep. Jason Altmire (D-PA)

    Total contributions: $67,500

  • #19. Sen. Ben Nelson (D-NE)

    Total contributions: $70,350

  • #18. Rep. Jim Gerlach (R-PA)

    Total contributions: $73,750

  • #17. Rep. Steny H. Hoyer (D-MD)

    Total contributions: $74,000

  • #16. Rep. Joe Pitts (R-PA)

    Total contributions: $76,000

  • #15. Rep. Dave Camp (R-MI)

    Total contributions: $76,500

  • #13 (tie). Rep. Kevin McCarthy (R-CA)

    Total contributions: $80,500

  • #13 (tie). Sen. Bob Corker (R-TN)

    Total contributions: $80,500

  • #12. Rep. James E. Clyburn (D-SC)

    Total contributions: $81,250

  • #11. Sen. Tom Carper (D-DE)

    Total contributions: $87,050

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »